Influenza, commonly known as the flu, is an acute respiratory illness caused by influenza viruses. It is highly contagious and spreads rapidly. Winter and spring are the peak seasons for influenza epidemics and transmission. Most people are susceptible to the flu, and high-risk groups includechildren <5 years old, elderly people ≥65 years old, pregnant and postpartum women, and those with chronic diseases or weakened immune systems. Serious complications, such as pneumonia, can lead to severe influenza in some children under 2 years old, necessitating vigilance from parents and healthcare professionals. According to the World Health Organization (WHO), about 20% to 30% of children worldwide contract seasonal influenza each year. During high-prevalence seasons, the infection rate in children can reach up to approximately 50%. Influenza has a swift onset, and while most symptoms are resolved without medical intervention, some patients may experience severe cases due to complications, potentially progressing to acute respiratory distress syndrome (ARDS), multi-organ failure, and even death.

 

There are two primary methods for viral antigen detection: direct fluorescent antibody detection and immunocolloidal gold chromatography. Direct fluorescent antibody detection involves labeling antibody molecules with fluorescent dyes and binding them to specific antigens in the specimen, which are then observed using a fluorescence microscope. Immunocolloidal gold chromatography is a user-friendly technique that doesn’t require specialized equipment, providing intuitive detection results and being suitable for use at the grassroots level. Influenza A and B virus antigen detection using colloidal gold immunochromatography can rapidly and conveniently detect influenza virus antigens by collecting nasopharyngeal swab samples.

 

The R&D team at Seebio Biotechnology has developed two pairs of high-quality matched antibodies against influenza A and B viruses, screened and validated multiple antibodies, and utilized them for the detection of influenza A/B virus antigens in enzyme-linked immunoassays, immunochromatography, and other platforms. Additionally, recombinant proteins of influenza A/B viruses were produced for calibration and quality control purposes. Seebio Biotech also offers conventional reagents and consumables for immunochromatography platforms.

 

 

Core Raw Materials：

 

 

Related Products：